Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to ...

Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline.

WASHINGTON, D.C.—FDA Commissioner Martin Makary, M.D., offered more details into the agency’s recently announced plans to ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

Julius Clinical is intertwining its roots with those of Peachtree BioResearch Solutions. | Netherlands-based Julius Clinical ...